Volume : 08, Issue : 08, August – 2021

Title:

60.PHARMACOLOGICAL TREATMENT OF DIABETES AND SIDE EFFECTS

Authors :

Fatimah Abdullah Abu Abdullah, Fedaa Ahmed Al-Zaher, Zahra Hussain Suhail, Zahra Ali Abu Alrehi, Suad Abdullah Al-Nasser, Aida Ali Abdulwahab, Mohammed Marai Ali Al Dukain, Nada Abdulmohsen Al Faraj, Amira Abdullah Alabbad, Zahraa Abdulkarim Alnass, Zainab Saleh Almadeh, Amal Habib Al Suliman, Asma Naji Al Huwaidi, Zainab Ibraheem Al Fadhel, Houriah Abdullah Hussien Tarmoukh

 

Abstract :

VThe pharmacological treatment of diabetes involves various medications, each with distinct mechanisms of action and side effect profiles. Choosing the proper treatment involves a multifaceted approach that considers the type of diabetes, the root cause, and the economic factors of available therapies. Overall, the choice of diabetes treatment should be a collaborative process between the patient and healthcare provider, integrating clinical evidence, patient preferences, and lifestyle considerations to optimize outcomes and ensure adherence to the treatment plan
Keywords: Diabetes, Insulin, Metformin, Sulfonylureas, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Meglitinides, Amylin Analogues

Cite This Article:

Please cite this article in press Fatimah Abdullah Abu Abdullah et al., Pharmacological Treatment Of Diabetes And Side Effects.., Indo Am. J. P. Sci, 2021; 08(08).

Number of Downloads : 10

References:

1. STILLMAN E. THE CONTROL OF ACIDOSIS IN THE TREATMENT OF DIABETES. Archives of Internal Medicine. 1919;24(4):445-57.
2. Shen S-W, Bressler R. Clinical Pharmacology of Oral Antidiabetic Agents. New England Journal of Medicine. 1977;296(9):493-7.
3. Bloomgarden ZT. Pharmacologic Treatment of Type 2 Diabetes. Diabetes Care. 2003;26(2):526-33.
4. Cefalu WJCp, therapeutics. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. 2007;81(5):636-49.
5. El-Kaissi S, Sherbeeni SJCdr. Pharmacological management of type 2 diabetes mellitus: an update. 2011;7(6):392-405.
6. Rajkumar J, Kaushal J, Gupta M, Verma SJJoDD, Therapeutics. Journal of Drug Discovery and Therapeutics 1 (7) 2013, 53-62. 2013;1(7):53-62.
7. Laight D. The pharmacology of oral antidiabetic agents. 2014;12(12):604-7.
8. Eyadeh AA, Jennings PE, Phillips A. New pharmacological approaches to diabetes management. 2015;26(3):140-6.
9. Cefalu WT, Rosenstock J, LeRoith D, Riddle MC. Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”. Diabetes Care. 2015;38(12):2200-3.
10. Theuma R. Insulin in the management of diabetes mellitus. 2008.
11. Kamran MAA. Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics – A Scientific Research Review. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued). 2012;6(2):148-70.
12. Chacra AR. Evolving Metformin Treatment Strategies in Type-2 Diabetes: From Immediate-Release Metformin Monotherapy to Extended-Release Combination Therapy. 2014;21(3):198-210.
13. Fiad T, Al Hammadi F, Al Nuaimi A, Al Dhuhouri JJIJoM, Sciences B. Emerging concepts in metformin therapy: Hyperglycaemia and beyond. 2013;5(04):227-39.
14. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. 2008;5(3):157-67.
15. Berne C, Campbell IW. Metformin is the lifelong partner in diabetes management: true or false?:A report from a symposium held on the occasion of the 46th Annual Meeting of the EASD, Stockholm, 20-24 September, 2010. 2011;11(1):42-51.
16. Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, Inoue N, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. 2013;6(298):ra94-ra.
17. Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. 2015;19(5):577-96.
18. Guillausseau P-JJCDR. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed. 2011;11(6):461-2.
19. Thulé PM, Umpierrez GJCdr. Sulfonylureas: a new look at old therapy. 2014;14:1-8.
20. Hwang Y-CJE, Metabolism. Sulfonylurea: Personalized Medicine for Type 2 Diabetes. 2015;30(4):467-8.
21. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. 2015;42(10):999-1024.
22. Pantaleão SQ, Maltarollo VG, Araujo SC, Gertrudes JC, Honorio KMJMB. Molecular docking studies and 2D analyses of DPP-4 inhibitors as candidates in the treatment of diabetes. 2015;11(11):3188-93.
23. Zhong J, Maiseyeu A, Davis SN, Rajagopalan SJCr. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. 2015;116(8):1491-504.
24. Lee SAJTJoKD. DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. 2013;14(3):128-32.
25. Omar B, Ahrén BJD. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. 2014;63(7):2196-202.
26. Shaefer Jr CF, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine. 2015;127(8):818-26.
27. Unger JJCdr. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. 2013;13(5):663-8.
28. Scheen AJJCp. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. 2015;54:691-708.
29. Nauck MAJDd, development, therapy. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. 2014:1380-.
30. Verbrugge FH, Vangoitsenhoven R, Mullens W, Van der Schueren B, Mathieu C, Tang WWJCCRR. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes? 2015;9:1-8.
31. DeFronzo RA, Mehta RJ, Schnure JJJHp. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. 2013;41(2):132-47.
32. Suvag S, Utzschneider KM, Kahn SE. Treatment with Thiazolidinediones. H. Beck-Nielsen (ed.), The Metabolic Syndrome. DOI 10.1007/978-3-7091-1331-8_9,# Springer-Verlag Wien; 2013.
33. S Papaetis G, Orphanidou D, N Panagiotou TJCdt. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. 2011;12(10):1498-512.
34. Goel OP. Thiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes. Google Patents; 2016.
35. Hanefeld M, Mertes G. Treatment: Alpha Glucosidase Inhibitors. In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases (Second Edition). Oxford: Academic Press; 2019. p. 238-44.
36. Patel SJH, Research M. Cerebrovascular complications of diabetes: alpha glucosidase inhibitor as potential therapy. 2016;48(02):83-91.
37. Hanefeld M, Mertes G. Treatment: alpha glucosidase inhibitors. 2019.
38. Derosa G, Maffioli PJAomsA. α-Glucosidase inhibitors and their use in clinical practice. 2012;8(5):899.
39. Malaisse WJJTie. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. 2003;2:401-14.
40. Davies M, Chatterjee SJIToDM. Meglitinides: Basic Aspects and Clinical Uses. 2003.
41. Rudovich N, Möhlig M, Otto B, Pivovarova O, Spranger J, Weickert MO, et al. Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. 2010;12(1):57-64.
42. Adeghate E, Kalász HJTomcj. Suppl 2: amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. 2011;5:78.
43. Tripathi AS, Wadhwani PJ, Majumder PM, Chandewar AV, Marathe S, Mahajan PGJIJoDiDC. Amylin dual action: a second gluco regulatory β-cell hormone, treatment and cause for the diabetes. 2014;34:125-9.